Catalyst Pharmaceuticals Inc (CPRX)

May 03, 2025

BlackRock, Inc. Reduces Stake in Catalyst Pharmaceuticals Inc - GuruFocus

May 03, 2025

Apr 30, 2025

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities H - GuruFocus

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - The Manila Times

Apr 30, 2025

Apr 30, 2025

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist? - Yahoo Finance

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals Leadership Team to Share Rare Disease Strategy at Major BofA Healthcare Conference - Stock Titan

Apr 30, 2025

Apr 28, 2025

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock performs better than its underlying earnings growth over last five years - simplywall.st

Apr 28, 2025

Apr 27, 2025

Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now - MSN

Apr 27, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch

Apr 25, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 | CPRX Stock News - GuruFocus

Apr 22, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Release First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Nasdaq

Apr 22, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewswire

Apr 22, 2025

Apr 22, 2025

Earnings Watch: When Catalyst Pharmaceuticals Will Reveal Q1 2025 ResultsKey Date for Rare Disease Leader - Stock Titan

Apr 22, 2025

Apr 21, 2025

BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33 - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from Bof - GuruFocus

Apr 21, 2025

Apr 21, 2025

Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from BofA to $34 | CPRX Stock News - GuruFocus

Apr 21, 2025

Apr 17, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 15, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 15, 2025

Apr 11, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - MSN

Apr 11, 2025

Apr 11, 2025

11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey

Apr 11, 2025

Apr 09, 2025

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace

Apr 09, 2025

Apr 08, 2025

Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan

Apr 08, 2025

Apr 08, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy – Company AnnouncementFT.com - Financial Times

Apr 08, 2025

Apr 07, 2025

Lambert Eaton Myasthenic Syndrome Market 2025: Growth, - openPR.com

Apr 07, 2025

Apr 03, 2025

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN

Apr 02, 2025

Apr 02, 2025

Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Apr 02, 2025

Apr 01, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 01, 2025

Mar 31, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Mar 31, 2025

Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Mar 31, 2025

Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN

Mar 27, 2025

Mar 26, 2025

Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire

Mar 26, 2025

Mar 25, 2025

With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st

Mar 25, 2025

Mar 24, 2025

CPRX stock soars to all-time high of $24.8 amid robust growth - Investing.com

Mar 24, 2025

Mar 24, 2025

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.

Mar 24, 2025

Mar 17, 2025

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance

Mar 17, 2025

Mar 14, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025